Supercharging clinical trials with data and AI: Realyze’s Aaron Brauser on faster, smarter design

Optimising clinical trial screening requires clinical expertise and, now, artificial intelligence, reducing patient screening time and boosting trial enrolment, as well as addressing the risk of overtreatment.

At ASCO 2025, web editor Nicole Raleigh spoke with Aaron Brauser, co-founder and CEO of Realyze Intelligence Healthcare Solutions, a Carta Healthcare company, about accelerating clinical trial and delivering real-world data (RWD).

Brauser discusses how pharma can leverage precision medicine tools to better target therapies and support value-based care initiatives, and how industry can interpret electronic-health records (EHRs) to identify real-world endpoints and optimise clinical trial design. He also explains the role of natural language processing (NLP) and AI here.

Take a watch of the video and be sure to catch up on other content from ASCO 2025 in Chicago, too.